Varian gets China OK for Halcyon system

Radiation oncology firm Varian Medical Systems has received clearance for its...Read more on AuntMinnie.comRelated Reading: Varian launches Bravos brachytherapy system Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona Varian signs educational partner in India
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

CONCLUSION: Dose escalation with hypofractionated proton boost was as effective as reported with high dose-rate brachytherapy boost, and the GU and GI toxicity profile was very similar. The proton boost was also appropriate for patients with larger prostate volume, higher T-stage, and high-risk disease encompassing elective regional node photon therapy. PMID: 31431382 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Purpose of review To discuss alternative strategies for multimodal treatments of nonmetastatic bladder–prostate rhabdomyosarcoma performed with the aim of preserving organ function. Recent findings Bladder–prostate rhabdomyosarcomas are seldom fully resectable at presentation or after induction chemotherapy, and extensive resection might not improve survival. When an organ-sparing approach is pursued, radiotherapy might be unavoidable to achieve reliable local control of the disease. Benefits of preoperative vs. postoperative radiotherapy have yet to be investigated. Multimodal treatments may often result ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: PAEDIATRIC URO-ONCOLOGY: Edited by Manuela P. Hiess Source Type: research
Ocular proton therapy (OPT) is considered the elective treatment for different kinds of highly malignant intraocular tumor. Uveal, iris and conjunctival melanomas, ocular hemangioma and retinoblastomas are amongst the lesions typically treated with OPT, particularly if target thickness prevents the applicability of other treatment modalities such as brachytherapy [1 –4]. A remarkable local control rate (well over 90%) was reported over the years by several institutions with over 28.000 patients treated worldwide [1,5,6], even though concomitant counter-effects, such as radiation induced damage to the lacrimal gland, ...
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
The U.S. Trade Representative has approved a request from radiation oncology...Read more on AuntMinnie.comRelated Reading: Varian gets China OK for Halcyon system Varian launches Bravos brachytherapy system Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Radiation oncology firm Varian Medical Systems has introduced Bravos, a new...Read more on AuntMinnie.comRelated Reading: Varian posts mixed results for fiscal 2018 Varian launches single-room proton therapy at ASTRO Varian acquires oncology software company Noona Varian signs educational partner in India Varian makes changes at 2 divisions
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Authors: Podder TK, Fredman ET, Ellis RJ Abstract Major categories of radiotherapy (RT) for prostate cancer (CaP) treatment are: (1) external beam RT (EBRT), and (2) brachytherapy (BT). EBRT are performed using different techniques like three-dimensional conformal RT (3D-CRT), intensity modulated RT (IMRT), volumetric modulated arc therapy (VMAT), and stereotactic body radiation therapy (SBRT), stereotactic radiosurgery (SRS) and intensity modulated proton therapy (IMPT), etc., using a variety of radiation delivery machines, such as a linear accelerator (Linac), Cyberknife robotic system, Gamma knife, Tomotherapy a...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Eye-preservation using brachytherapy (BT) and proton therapy (PT) are commonly used as primary treatments for uveal melanomas (UM). Choice of modality generally depends on local availability rather than direct assessment of the two techniques. We conducted a comparative dose planning study, estimating biologically effective doses (BED) to the tumour, macula and optic nerve head (ONH).
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Source Type: research
Age-related macular degeneration (AMD) is the leading cause of blindness in aging adults and affects millions of patients in the U.S. and even more worldwide. Existing treatments of the most devastating neovascular form of AMD involve monthly injections into the eye(s) of patients, who typically are elderly. These injections are costly and burdensome, requiring periodic intraocular injections for drug delivery. Radiation has been used to treat AMD: 6 MV external-beam radiation irradiation, proton therapy, and most recently stereotactic x-rays and beta applicators.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
In vivo dosimetry (IVD) is an important component of a comprehensive quality assurance program as a final check at the point of radiotherapy delivery; IVD can measure target doses, prevent dose delivery errors, and enhance the standard of patient care. IVD has been widely used in conventional external beam radiotherapy [1] and brachytherapy [2]. In external beam radiotherapy, IVD is mostly used for entrance dose measurement because it is easy to place a detector on the skin of the patient. For photon beam radiotherapy, transmission measurements using an electronic portal imaging device (EPID) are also gaining interest for IVD [3].
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
This article aims to review the complex RMS classification system and treatment of BP RMS, with a focus on developing aspects of treat ment.Recent FindingsRecent advancements in technology are responsible for most of the progress in RMS treatment. PET-CT scanning has been shown to be superior to conventional metastatic workup. The use of proton beam therapy and brachytherapy to reduce the side effects of radiation is also showing promise.SummaryAll cooperative oncology groups agree on surgical biopsy for diagnosis and staging of BP RMS. Patients are then grouped and risk classified before receiving chemotherapy. Regardless...
Source: Current Urology Reports - Category: Urology & Nephrology Source Type: research
More News: Brachytherapy | Cancer & Oncology | China Health | Education | India Health | Proton Therapy